In Vitro, In Silico and Ex Vivo Studies of Dihydroartemisinin Derivatives as Antitubercular Agents

(E-pub Ahead of Print)

Author(s): Komal Kalani, Sarfraz Alam, Vineeta Chaturvedi, Feroz Khan, Santosh Kumar Srivastava*.

Journal Name: Current Topics in Medicinal Chemistry

Become EABM
Become Reviewer


As a part of our drug discovery program for anti-tubercular agents, dihydroartemisinin (DHA- 1) was screened against Mtb H37Rv, which showed moderate anti-tubercular activity (>25 .0 μg/mL). These results prompted us to carry out the chemical transformation of DHA-1 into various derivatives and study their antitubercular potential. Thus, DHA-1was semi-synthetically converted into four new acyl derivatives (DHA-1A – DHA-1D) and in-vitro evaluated for their anti-tubercular potential against Mycobacterium tuberculosis H37Rv virulent strain. The derivatives, DHA-1C (12-O-(4-nitro) benzoyl; MIC 12.5 μg/mL) and DHA-1D (12-O-chloro acetyl; MIC 3.12μg/mL) showed significant activity against the pathogen. Further, in silico studies of the most active derivative (DHA-1D) showed interaction with ARG448 inhibiting the mycobacterium enzymes. Additionally, it showed no cytotoxicity towards the Vero C1008 cells and Mouse bone marrow derived macrophages. Finally, DHA-1D also killed 62% intracellular M. tuberculosis in Mouse bone marrow macrophage infection model. To the best of our knowledge, this is the first-ever report on the antitubercular potential of dihydroartemisinin and its derivatives. Since dihydroartemisinin is widely used as an antimalarial drug; these results may be of great help in anti-tubercular drug development from a very common, inexpensive, and non-toxic natural product.

Keywords: Dihydroartemisinin, semi-synthetic derivatives, anti-tubercular activity, in-silico studies

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1568026619666190305131425
Price: $95